Algeness
Algeness (Advanced Aesthetic Technologies, Inc.) develops and commercializes patented agarose gel-based injectable dermal fillers, selling a four-product family (DF, VL, HD, LD) exclusively to certified aesthetic physicians through 50+ distributors across 30+ countries, with CE Mark and recent China NMPA approval.
- Company typePrivate
- Founded2010
- HeadquartersBrookline, United States
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
What Algeness does
Advanced Aesthetic Technologies, Inc. (AAT), operating under the brand Algeness, is a privately held biotechnology company headquartered in Brookline, Massachusetts with a European subsidiary in Dublin, Ireland. The company develops, manufactures, and commercializes a family of patented injectable dermal fillers based on purified agarose gel — a 100% natural, biodegradable, and biocompatible polymer derived from algae that achieves volumetric and structural support without synthetic cross-linking agents such as BDDE or PEG. Its four-product portfolio (DF 3.5%, VL 2.5%, HD 1.5%, LD 1%) is differentiated by agarose concentration and biophysical properties (high G' elasticity and G'' viscosity) and is supported by a proprietary injection technique branded as 'Master Your Results.' A peer-reviewed split-face clinical study published in the Journal of Cosmetic Dermatology demonstrated equivalent efficacy of Algeness VL to NASHA-L hyaluronic acid filler for nasolabial fold correction.
Algeness operates a B2B enterprise distribution model, selling exclusively to certified aesthetic physicians, plastic surgeons, and dermatologists through a global network of 50+ regional distributors across 30+ countries. The company does not sell directly to consumers; all practitioners must complete Algeness's mandatory training and certification program before purchasing and administering products. Pricing is not publicly disclosed and is established quote-by-quote between AAT and its distributor network. CE MDR approval was obtained in January 2023, and NMPA marketing approval for Algeness VL in China was secured in January 2025 via exclusive partner Lanzhou Biotechnique Development Co. (LanDev), a subsidiary of China National Biotec Group (CNBG). CNBG holds a major but non-controlling equity position in AAT dating to September 2019.
The company is pursuing US FDA registration and additional country-level approvals as its principal growth drivers. Marketing and commercial activities are concentrated around aesthetic medicine congresses (AMWC, IMCAS, Dubai Derma), peer-reviewed clinical publications, and a physician testimonial network. Headcount is reported at 1-10 employees, consistent with a lean, asset-light operating model that depends on distributor partners for in-country sales infrastructure. AAT is led by President and CEO Doug Abel, with a board chaired by Peter Rogal and including a CNBG representative.
Algeness firmographics
Firmographics- Name
- Algeness
- Legal name
- Advanced Aesthetic Technologies, Inc.
- Website
- https://algeness.com
- Company type
- Private
- Founded year
- 2010
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- Algeness (Advanced Aesthetic Technologies, Inc.) develops and commercializes patented agarose gel-based injectable dermal fillers, selling a four-product family (DF, VL, HD, LD) exclusively to certified aesthetic physicians through 50+ distributors across 30+ countries, with CE Mark and recent China NMPA approval.
- Ownership category
- akta.pro rank
Algeness industry classification
Industry- Product category
- Aesthetic medical devices (injectable dermal fillers)
- NAICS
- Pharmaceutical Preparation Manufacturing (325412)
- SIC
- Perfumes, Cosmetics & Other Toilet Preparations (2844), Medicinal Chemicals & Botanical Products (2833)
- akta.pro primary industry
- Dermocosmetics & Medical-Grade Skincare (CRABAAAF)
Keywords
Where Algeness is headquartered
LocationHeadquarters
- HQ city
- Brookline
- HQ country
- United States
- HQ region
- North America
Offices2 records
Markets served
Algeness business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Marketing or Sales, Supply Chain, Personnel, Operations, Infrastructure
Revenue model
- Dermal Filler Product Sales: Algeness generates revenue through the sale of its four agarose-based injectable dermal filler products (DF, VL, HD, LD) to certified aesthetic physicians and plastic surgeons via a global distributor network. The company sells directly through distributor partnerships across Europe, Americas, Middle East, Africa, and Asia. Revenue is derived from product unit sales to medical professionals.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Unit Pricing | Pay-as-you-go | Four agarose concentration products: DF (High Density), VL (Medium-High), HD (Medium), LD (Low) |
Go-to-market motion1 record
Distribution channels4 records
Marketing channels7 records
Algeness product offering
Product offeringCore offering
Algeness develops and sells a patented family of injectable dermal fillers based on 100% natural, purified agarose gel derived from algae. The four-concentration product line (DF 3.5%, VL 2.5%, HD 1.5%, LD 1%) is designed for deep structural volumization, facial contouring, and wrinkle correction, and is sold only to certified aesthetic physicians, dermatologists, and plastic surgeons through a global distributor network.
Product overview
Algeness is a family of four injectable dermal filler products based on purified agarose gel derived from algae. The product portfolio includes ALGENESS DF (3.5%), VL (2.5%), HD (1.5%), and LD (1%) representing different concentrations and densities for varying treatment applications. The fillers are 100% natural, biodegradable, and biocompatible with no synthetic cross-linking chemicals, providing immediate visible results with minimal swelling. Treatment applications include chin projection, jawline definition, nose correction, and zygomatic arch volumization. The company also offers a proprietary injection technique called Master Your Results®.
Differentiator
Problem solved
Functional benefit
Products and services
- ALGENESS DF 3.5% purified agarose gel filler with high density, designed for deep structural volumization and facial contouring applications requiring maximum projection (cheekbones, jawline, chin, zygomatic arch). For certified aesthetic physicians and plastic surgeons.
- ALGENESS VL 2.5% purified agarose gel filler with medium-high density, used for nasolabial fold correction and general facial volumization. Clinically validated as equivalent in efficacy to NASHA-L hyaluronic acid fillers.
- ALGENESS HD 1.5% purified agarose gel filler with medium density, designed for mid-density facial applications and moderate volumization needs.
- ALGENESS LD 1% purified agarose gel filler with low density, intended for fine line correction, lip augmentation, and superficial tissue applications requiring minimal projection.
Quantifiable outcome
- Equivalent efficacy to NASHA-L hyaluronic acid filler for nasolabial fold correction (mean WSRS change of -1.1 ± 0.4 for both products at 3 months)
- +6 more outcomes
Companies that use Algeness
Customer profileNamed customers7 records
Segments3 records
Ideal customer profiles2 records
Algeness technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature5 records
Algeness partnerships and signals
Strategic signalPartnerships
Two partnerships are on record, tiered flagship.
- Lanzhou Biotechnique Development Co., Ltd. (LanDev)flagshipLanDev, a subsidiary of CNBG, is the exclusive partner responsible for obtaining Chinese regulatory approvals (NMPA) and distribution of Algeness products in mainland China. LanDev is the exclusive manufacturer of botulinum toxin A (Hengli®) in China with ~70% market share for BTXA. LanDev also holds exclusive distribution rights for Princess hyaluronic acid fillers (CROMA-Pharma) in mainland China and a strategic partnership with Cynosure. LanDev obtained approval for Algeness VL in January 2025.
- China National Biotec Group Co., Ltd. (CNBG)flagshipStrategic cooperation agreement executed September 2019 between AAT and CNBG, a subsidiary of China National Pharmaceutical Group (Sinopharm). CNBG took a major but non-controlling equity position in AAT in exchange for an investment. The partnership grants LanDev (CNBG subsidiary) exclusive rights for regulatory approval and distribution of Algeness products in mainland China. CNBG is China's largest biopharmaceutical company and the largest producer/supplier of vaccines and plasma products in China. CNBG holds approximately 77% market share for botulinum toxin A in China.
Scale indicators9 records
Recent moves6 records
Expansion highlights5 records
Algeness competitors and assessment
Company assessmentEmerging players
- Suneva Medical: US aesthetics company behind Bellafill, a PMMA-based permanent non-HA dermal filler. Closest peer in differentiated, non-HA filler chemistry targeting deep facial volumization and structural augmentation.
- Prollenium Medical Technologies: Canadian independent maker of the Revanesse HA dermal filler line. Comparable privately scaled aesthetics company competing in the same physician accounts with injectable fillers.
Regional players
- Evolus: Aesthetics specialty company commercializing the Jeuveau neuromodulator. Different product category (botulinum toxin vs. filler), but addresses the same core physician customer base in medical aesthetic clinics.
Direct peers
- Revance Therapeutics: Maker of the RHA resilient HA filler line and the Daxxify neuromodulator. A focused injectable aesthetics competitor using differentiated chemistry to position against legacy HA brands.
- Merz Aesthetics: Maker of Radiesse (CaHA) and Belotero (HA) dermal fillers plus Ultherapy. Most direct competitor to Algeness in deep structural volumization, with a parallel non-HA filler chemistry story.
- Galderma: World's largest pure-play dermatology/aesthetics company and maker of the Restylane HA filler family, Sculptra (PLLA), and Dysport. Direct head-to-head competitor to Algeness in physician-dispensed dermal fillers for facial volumization.
- Sinclair Pharma: UK-headquartered aesthetics company with Ellansé (PCL collagen-stimulator) and MaiLi HA fillers. Closest peer to Algeness in differentiated, non-HA bio-stimulatory dermal filler chemistry.
- Teoxane: Swiss aesthetics company selling the Teosyal HA dermal filler range globally. Operates in the same physician-channel, injectable-filler category that Algeness targets.
- Croma-Pharma: Austrian maker of Princess HA fillers with broad international distribution. Notably also distributed in mainland China by Algeness's Chinese partner LanDev — making it the closest like-for-like HA filler comparator.
Broad incumbents
- Allergan Aesthetics (AbbVie): Largest aesthetics platform globally; maker of the Juvéderm HA filler family, BOTOX, and CoolSculpting. The dominant incumbent whose HA franchise Algeness must displace in aesthetic clinic accounts.
Market position
Strengths4 records
Weaknesses5 records
Competitive moat4 records
Key risks5 records
Key highlights6 records
Customer concentration
Algeness social profiles
Digital presenceAlgeness compliance and trust
Trust signalCompliance4 records
Algeness financial estimates
Financial estimateRevenue estimate
Valuation estimate
Algeness leadership team
Management profileNumber of profiles
Profiles6 records
Algeness subsidiaries and ownership
Company hierarchySubsidiaries1 record
Algeness funding detail
Funding detailFunding overview
Funding rounds1 record
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Algeness M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Algeness
What does Algeness do?
Algeness develops and sells a patented family of injectable dermal fillers based on 100% natural, purified agarose gel derived from algae. The four-concentration product line (DF 3.5%, VL 2.5%, HD 1.5%, LD 1%) is designed for deep structural volumization, facial contouring, and wrinkle correction, and is sold only to certified aesthetic physicians, dermatologists, and plastic surgeons through a global distributor network.
Is Algeness a public or private company?
Algeness is a private company. It is classified as venture growth investor backed and is currently operating.
When was Algeness founded?
Algeness was founded in 2010. It employs 1 to 10 people.
Where is Algeness based?
Algeness is headquartered in Brookline, United States, in the North America region.
How does Algeness make money?
One revenue line is on record: dermal Filler Product Sales.
Who are Algeness's main competitors?
Emerging players on record are Suneva Medical and Prollenium Medical Technologies. Evolus is listed as a regional player. Direct peers are Revance Therapeutics, Merz Aesthetics, Galderma, Sinclair Pharma, Teoxane and Croma-Pharma. Allergan Aesthetics (AbbVie) is listed as a broad incumbent.
Does Algeness have an API?
No public API is recorded for Algeness.
What industry is Algeness in?
Algeness's product category is Aesthetic medical devices (injectable dermal fillers). Its primary akta.pro industry code is CRABAAAF, Dermocosmetics & Medical-Grade Skincare. Its NAICS code is 325412 and its SIC code is 2844.